Pharmacological Predictors of Morbidity and Mortality in COVID-19
| Autor: | Hannah Morrison, Polly Keeling, Dhanuja Senn, Christopher Oddy, Thomas Samuel, Neesha Soni, Ruwani Mawella, John Dixon, Jonathan Allington, James McCaul |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Statin Prescription Drugs medicine.drug_class Proton-pump inhibitor Original Manuscript propensity score matched Risk Assessment Severity of Illness Index SARS‐CoV‐2 COVID-19 Testing medications COVID‐19 Internal medicine medicine Humans Pharmacology (medical) Gliclazide Medical prescription Propensity Score Contraindication Critical Care Outcomes Aged Retrospective Studies Pharmacology business.industry SARS-CoV-2 COVID-19 Retrospective cohort study United Kingdom Hospitalization prescriptions Cohort Propensity score matching Female business medicine.drug severe acute respiratory syndrome coronavirus 2 |
| Zdroj: | Journal of Clinical Pharmacology |
| ISSN: | 1552-4604 |
| Popis: | The interaction of coronavirus disease (COVID-19) with the majority of common prescriptions is broadly unknown. The purpose of this study is to identify medications associated with altered disease outcomes in COVID-19. A retrospective cohort composed of all adult inpatient admissions to our center with COVID-19 was analyzed. Data concerning all antecedent prescriptions were collected and agents brought forward for analysis if prescribed to at least 20 patients in our cohort. Forty-two medications and 22 classes of medication were examined. Groups were propensity score matched and analyzed by logistic and linear regression. The majority of medications did not show a statistically significant relationship with altered disease outcomes. Lower mortality was associated with use of pregabalin (hazard ratio [HR], 0.10; 95% confidence interval [CI], 0.01-0.92; P = .049) and inhalers of any type (HR, 0.33; 95%CI, 0.14-0.80; P = .015), specifically beclomethasone (HR, 0.10; 95%CI, 0.01-0.82; P = .032), tiotropium (HR, 0.07; 95%CI, 0.01-0.83; P = .035), and steroid-containing inhalers (HR, 0.35; 95%CI, 0.15-0.79; P = .013). Gliclazide (HR, 4.37; 95%CI, 1.26-15.18; P = .020) and proton pump inhibitor (HR, 1.72; 95%CI, 1.06-2.79; P = .028) use was associated with greater mortality. Diuretic (HR, 0.07; 95%CI, 0.01-0.37; P = .002) and statin (HR, 0.35; 95%CI, 0.17-0.73; P = .006) use was associated with lower rates of critical care admission. Our data lends confidence to observing usual practice in patients with COVID-19 by continuing antecedent prescriptions in the absence of an alternative acute contraindication. We highlight potential benefits in investigation of diuretics, inhalers, pregabalin, and statins as therapeutic agents for COVID-19 and support further assessment of the safety of gliclazide and proton pump inhibitors in the acute illness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text